Rainbow Coral (RBCC) 10-K/A 6 Aug 14 2014 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Mar. 31, 2014	Jul. 30, 2014	Sep. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Mar-14	'	'
Entity Registrant Name	'RAINBOW CORAL CORP.	'	'
Entity Central Index Key	'0001499790	'	'
Current Fiscal Year End Date	'--03-31	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$1,386,604
Entity Units Outstanding	'	26,851,900	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Mar. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$65,373	$84,592
Prepaid expenses	841	350
Inventory	5,249	29,020
Total current assets	71,463	113,962
Fixed assets net of accumulated depreciation of $7,615 and $1,760, respectively	6,282	5,428
Goodwill	'	27,868
TOTAL ASSETS	77,745	147,258
CURRENT LIABILITIES	'	'
Accounts payable and accrued liabilities	191,780	117,351
Advances payable	149,453	133,455
Related party advances payable	131,505	94,881
Current portion of notes payable	2,843	'
Current portion of convertible notes payable, net of discount of $0 and $3,491, respectively	'	1,024
Total current liabilities	475,581	346,711
Convertible notes payable, net of discount of $215,716 and $193,607, respectively.	13,111	24,576
Notes payable	47,157	'
Accrued interest payable	11,201	10,929
TOTAL LIABILITIES	547,050	382,216
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' DEFICIT	'	'
Preferred Stock, $0.0001 stated value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2014 and March 31, 2013, respectively.	'	'
Common Stock, $0.0001 par value; 100,000,000 shares authorized. 22,851,900 and 12,519,828 shares issued and outstanding at March 31, 2014 and March 31, 2013, respectively.	2,285	1,252
Additional paid-in capital	2,460,965	1,599,204
Accumulated deficit	-2,932,555	-1,835,414
Total stockholders' deficit	-469,305	-234,958
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$77,745	$147,258

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED BALANCE SHEETS [Abstract]	'	'
Accumulated depreciation	$7,615	$1,760
Current portion of convertible notes payable discount	'	3,491
Noncurrent convertible notes payable discount	$215,716	$193,607
Preferred Stock, par value per share	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value per share	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	22,851,900	12,519,828
Common Stock, shares outstanding	22,851,900	12,519,828

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]	'	'
REVENUE	$113,009	$100,186
COST OF GOODS SOLD	113,228	69,385
GROSS PROFIT	-219	30,801
OPERATING EXPENSES	'	'
Expenses related to joint ventures and other business development agreements	85,000	'
General and administrative expenses	557,031	1,026,342
Impairment of goodwill	27,868	'
LOSS FROM OPERATIONS	-670,118	-995,541
OTHER EXPENSE	'	'
Interest expense	-427,023	-267,649
NET LOSS	($1,097,141)	($1,263,190)
NET LOSS PER COMMON SHARE - Basic and diluted	($0.07)	($0.18)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - Basic and diluted	16,636,020	6,921,485

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
BALANCE at Mar. 31, 2012	($183,224)	$58	$388,942	($572,224)
BALANCE, SHARES at Mar. 31, 2012	'	575,000	'	'
Share-based compensation	542,000	8	541,992	'
Share-based compensation, shares	'	80,000	'	'
Conversion of notes payable	224,022	1,186	222,836	'
Conversion of notes payable, shares	'	11,864,744	'	'
Share rounding as result of reverse split	'	84	'	'
Discount on issuance of convertible notes payable	445,434	'	445,434	'
Net loss	-1,263,190	'	'	-1,263,190
BALANCE at Mar. 31, 2013	-234,958	1,252	1,599,204	-1,835,414
BALANCE, SHARES at Mar. 31, 2013	12,519,828	12,519,828	'	'
Conversion of notes payable	446,109	1,033	445,076	'
Conversion of notes payable, shares	10,332,072	10,332,072	'	'
Discount on issuance of convertible notes payable	416,685	'	416,685	'
Net loss	-1,097,141	'	'	-1,097,141
BALANCE at Mar. 31, 2014	($469,305)	$2,285	$2,460,965	($2,932,555)
BALANCE, SHARES at Mar. 31, 2014	22,851,900	22,851,900	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($1,097,141)	($1,263,190)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization of discount on convertible notes payable	398,067	248,336
Impairment of goodwill	-27,868	'
Impairment of inventory	14,500	'
Depreciation	5,854	1,438
Stock-based compensation	'	542,000
Changes in operating assets and liabilities:	'	'
Inventory	9,271	-767
Prepaid expenses	-491	'
Accounts payable and accrued liabilities	74,429	79,616
Accrued interest payable	35,825	19,102
NET CASH USED IN OPERATING ACTIVITIES	-531,818	-373,465
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchase of fixed assets	-6,708	-406
NET CASH USED IN INVESTING ACTIVITIES	-6,708	-406
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from advances	432,683	396,138
Proceeds from related party advances	38,442	61,896
Repayments of related party advances	-1,818	-19,790
Proceeds from notes payable	50,000	'
NET CASH PROVIDED BY FINANCING ACTIVITIES	519,307	438,244
NET INCREASE (DECREASE) IN CASH	-19,219	64,373
CASH, at the beginning of the year	84,592	20,219
CASH, at the end of the year	65,373	84,592
Supplemental Disclosures of Cash Flow Information:	'	'
Interest	'	'
Taxes	'	'
Noncash investing and financing transactions:	'	'
Refinancing of advances into convertible notes payable	416,685	445,434
Beneficial conversion on convertible note payable	416,685	445,434
Conversion of convertible notes to common stock	$446,109	$224,022

Background_Information

Background Information	12 Months Ended
	Mar. 31, 2014
Background Information [Abstract]	'
Background Information	'
	Note 1. Background Information
	RAINBOW CORAL CORP. (the "Company"), a Florida corporation, was formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company's coral farming activity. We believe that the world of bio-research is a natural continuation of our core coral propagation business. Accordingly on October 23, 2011, the Company formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets.
	The Company was incorporated on August 13, 2010 with its corporate headquarters located in Miramar Beach, Florida.  The Company's fiscal year end March 31.
	Joint Ventures
	On March 13, 2012, the Company entered into a stock purchase agreement ("N3D Stock Purchase Agreement") with Nano3D Biosciences, Inc. ("N3D"), a Texas corporation that has developed a unique concept in three dimensional cell research tools. Under the terms of the N3D Stock Purchase Agreement, the Company agreed to acquire 604 shares of common stock of N3D, representing approximately 5% of the outstanding shares on the date of the agreement, for a price of $413.62 per share. The total purchase price of $249,826 was to be paid by making weekly payments of $5,000 until fully paid. Under the terms of the N3D Stock Purchase Agreement, we could discontinue payment of the purchase price at any time by providing written notice to N3D. The Company invested $60,000 in N3D resulting in the acquisition of 145 shares of N3D's common stock. The Company discontinued payments to N3D in May 2012 because of their delay in reaching certain milestones in the commercialization process.  The Company wrote off the investment in full due to the uncertainty about whether the carrying amount is recoverable.
	On February 1, 2013, the Company entered into a joint venture agreement with TheraKine Ltd. ("TheraKine") in order to explore potential business opportunities to exploit TheraKine's novel drug delivery technologies. TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. Under the terms of the joint venture agreement, the Company has committed to fund $55,000 of the cash flow requirements of the Joint Venture by making weekly payments of $6,875. During the year ended March 31, 2014, the Company made payments of $55,000 toward our joint venture.
	In January 2014, the Company began funding a second phase of its joint venture with TheraKine. During the year ended March 31, 2014, the Company expensed $30,000 related to this second phase, which was paid during the year. An additional $20,000 was paid and expensed subsequent to year end related to this agreement.

Going_Concern

Going Concern	12 Months Ended
	Mar. 31, 2014
Going Concern [Abstract]	'
Going Concern	'
	Note 2. Going Concern
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.
	The Company incurred a net loss of $1,097,141 during year ended March 31, 2014 and had net cash used in operating activities of $531,818 for the same period. In view of these matters, the Company's ability to continue as a going concern is dependent upon the Company's ability to achieve a level of profitability or to obtain adequate financing through the issuance of debt or equity in order to finance its operations. The Company intends to finance its future development activities and its working capital needs largely from the issuance of debt or convertible debt until such time that funds provided by operations are sufficient to fund working capital requirements. These factors raise substantial doubt about the Company's ability to continue as a going concern.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Note 3. Significant Accounting Policies
	The significant accounting policies that the Company follows are:
	Basis of Presentation
	The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The Financial Statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles ("GAAP") of the United States.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Principles of Consolidation
	The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the "Company"). All material intercompany accounts and transactions have been eliminated in consolidation.
	Cash and Cash Equivalents
	All cash is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Temporary cash investments with an original maturity of three months or less are considered cash equivalents. Cash and cash equivalents were $65,373 and $84,592 at March 31, 2014 and 2013, respectively.
	Inventory
	The Company follows ASC 330, Inventory. Inventory represents aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence. During the year ended March 31, 2014, the Company recognized a loss for impairment of inventory in the amount of $14,500.
	Fixed Assets
	Fixed assets of the Company include vehicles and computer equipment and are stated at cost. In accordance with ASC Topic 360, Property, Plant and Equipment, expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred.
	Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes.
	Impairment of long-lived assets
	Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value.
	Goodwill
	Goodwill represents the excess of purchase price and related costs over the value assigned to the net tangible and intangible assets of businesses acquired. We evaluate goodwill for impairment in accordance with ASC 350, Goodwill and Other. The Company recorded a goodwill impairment charge of $27,868 during the year ended March 31, 2014.
	Revenue and cost recognition
	In accordance with ASC 605, Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances.
	Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products which have been sold.
	Share-based Compensation Expense
	The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity - Based Payments to Non-Employees.  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
	Share-based expense for the years ended March 31, 2014 and 2013 was $0 and $542,000, respectively.
	Advertising Costs
	The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $23,239 and $73,749 of advertising costs for the fiscal years ended March 31, 2014 and 2013, respectively.
	Income Taxes
	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes resulting from temporary differences. Such temporary differences result from differences in the carrying value of assets and liabilities for tax and financial reporting purposes. The deferred tax assets and liabilities represent the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
	The Company adopted the provisions of FASB ASC 740-10 "Uncertainty in Income Taxes" (ASC 740-10). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.
	Earnings (Loss) Per Common Share
	The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.  For the years ended March 31, 2014 and 2013, the effect of common stock equivalents has been excluded from the calculation of diluted earnings per share as their effect would be anti-dilutive.  At March 31, 2014 and 2013, respectively, the Company had 6,000,704 and 5,219,669 potentially issuable shares upon the conversion of convertible notes payable and interest.
	Financial Instruments
	The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.
	FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
		Level 1 -	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
		Level 2 -	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		Level 3 -	Inputs that are both significant to the fair value measurement and unobservable.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
	Commitments and Contingencies
	The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no known commitments or contingencies as of March 31, 2014 and March 31, 2013.
	Recently Issued Accounting Pronouncements
	Recently issued or adopted accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Inventory

Inventory	12 Months Ended
	Mar. 31, 2014
Inventory [Abstract]	'
Inventory	'
	Note 4. Inventory
	Inventory consists of finished goods and is comprised of aquarium supplies.  The Company impaired $14,500 of inventory during 2014.

Advances

Advances	12 Months Ended
	Mar. 31, 2014
Advances [Abstract]	'
Advances	'
	Note 5. Advances
	During the year ended March 31, 2014, the Company received advances from Vista View Ventures Inc. in the amount of $432,683 for working capital. These advances are non-interest bearing and payable on demand. During the same period, the Company refinanced $416,685 of the advances into convertible notes payable with Vista View. As of March 31, 2014 and March 31, 2013, advances in the amount of $149,453 and $133,455, respectively, are included in current liabilities on the consolidated balance sheet.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Mar. 31, 2014
Convertible Notes Payable [Abstract]	'
Convertible Notes Payable	'
	Note 6. Convertible Notes Payable
	Convertible notes payable consist of the following as of March 31, 2014 and March 31, 2013:
		31-Mar-14			31-Mar-13
	Convertible note payable in the original principal amount of $192,600 due June 30, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.04 per share	$	4,742		$	-
	Convertible note payable in the original principal amount of $224,085 due Sepember 30, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.04 per share		224,085			-
	Convertible note payable in the original principal amount of $94,515, effective March 31, 2012 due March 31, 2014, bearing interest at 10% per year, convertible into common stock at a rate of $0.05 per share		-			4,515
	Convertible note payable in the original principal amount of $117,775, effective June 30, 2012 due June 30, 2014, bearing interest at 10% per year, convertible into common stock at a rate of $0.04 per share		-			73,275
	Convertible note payable in the original principal amount of $101,333, effective January 1, 2013 due January 1, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.05 per share		-			101,333
	Convertible note payable in the original principal amount of $43,575, effective March 31, 2013 due March 31, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.05 per share		-			43,575
	Total convertible notes payable		228,827			222,698
	Less: current portion of convertible notes payable		-			(4,515	)
	Less: discount on noncurrent convertible notes payable		(215,716	)		(193,607	)
	Long-term convertible notes payable, net of discount	$	13,111		$	24,576
	All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.
	During the year ended March 31, 2014, the Company entered into convertible promissory notes with Vista View Ventures, Inc. which refinanced non-interest bearing advances. The convertible notes have the following terms:
	Note Date	Maturity Date		Interest Rate		Conversion Rate		Loan Amount
	30-Jun-13	30-Jun-15		10%		$0.04 per share		$192,600
	30-Sep-13	30-Sep-15		10%		$0.04 per share		$224,085
	All principal along with accrued interest is payable on the maturity date.
	The Company evaluated the terms of the notes in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity's Own Stock and determined that the underlying common stock is indexed to the Company's common stock. The Company determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. The Company evaluated the conversion features for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the notes and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, the Company recognized a discount for the beneficial conversion feature in the amount of $416,685, in aggregate, on the date the notes were signed. The beneficial conversion feature was recorded as an increase in additional paid-in capital and a discount to the convertible notes payable. The discount to the convertible notes payable will be amortized to interest expense over the life of the note.
	During the year ended March 31, 2014, the holders of the convertible note payable dated March 31, 2012 elected to convert principal of $4,515 and accrued interest in the amount of $6,934 into 228,983 shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion at $0.05 per share.
	During the year ended March 31, 2014, the holders of the convertible note payable dated June 30, 2012 elected to convert principal of $73,275 and accrued interest of $8,702 into shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion at $0.04 per share.
	During the year ended March 31, 2014, the holders of the convertible note payable dated January 1, 2013 elected to convert principal of $101,333 and accrued interest in the amount of $5,354 into shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion at $0.05 per share.
	During the year ended March 31, 2014, the holders of the convertible note payable dated March 31, 2013 elected to convert principal of $43,575 and accrued interest in the amount of $2,421 into shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion at $0.05 per share.
	During the year ended March 31, 2014, the holders of the convertible note payable dated June 30, 2013 elected to convert principal of $187,858 and accrued interest in the amount of $12,142 into shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion at $0.04 per share.
	During the years ended March 31, 2014 and 2013, the Company received non-interest bearing advances of $432,683 and $396,138, respectively, from Vista View Ventures Inc.  The funds were advanced to the Company through an intermediary agent which also provides certain legal, accounting and support services to the Company.

Longterm_note_payable

Long-term note payable	12 Months Ended
	Mar. 31, 2014
Long-term note payable [Abstract]	'
Long-term note payable	'
	Note 7. Long-term note payable
	On December 30, 2013, the Company entered into a promissory note for $50,000 with a third party bearing interest at 5% per annum.  Under the terms of the note payable, the Company will begin making monthly payments on the note payable on January 1, 2015 over a period of 4 years.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Note 8. Related Party Transactions
	As of March 31, 2014 and 2013, related party advances payable were $131,505 and $94,881, respectively. The advances are payable to the President of the Company's Father Fish subsidiary and were used for working capital.

Income_Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	Note 9. Income Taxes
	There is no current or deferred income tax expense or benefit for the periods ended March 31, 2014 or 2013.
	The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference at March 31, 2014 and 2013 are as follows.
		2014			2013
	Tax benefit at U.S. statutory rate	$	370,000		$	195,000
	Amortization of discount on convertible notes payable		(160,000	)		-
	Valuation allowance		(210,000	)		(195,000	)
		$	-		$	-
	For the year ended March 31, 2014, the Company's only material temporary difference was the amortization of the discount on convertible notes payable as a result of recognizing a beneficial conversion feature. The Company did not have any material temporary differences for the year ended March 31, 2013.
	The tax returns for fiscal years 2011 through 2014 are still open for review by the Internal Revenue Service.
	The Company has not recognized an income tax benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	Note 10. Stockholders' Equity
	On March 5, 2012, the Company approved a 2012 Stock Plan for Directors, Officers and Consultants ("Plan") for the issuance of up to 6,000,000 shares of common stock or equivalent value, as determined. The Plan provides eligible employees and consultants the opportunity to participate in the enhancement of shareholder value by the grants of warrants, options, restricted common or convertible preferred stock if, as and when preferred stock is authorized by the Company and its shareholders, unrestricted common or convertible preferred stock and other awards under this Plan and to have their bonuses and/or consulting fees payable in warrants, restricted common or convertible preferred stock, unrestricted common or convertible preferred stock and other awards, or any combination thereof.
	Common stock issued for Services
	During the year ending March 31, 2014, the Company recorded no stock-based compensation expense.  During the year ending March 31, 2013, the Company recorded stock-based compensation of $542,000, in connection with the issuance of 80,000 shares for services.
	Conversion of Convertible Notes Payable
	During the year ended March 31, 2014, the Company issued 10,332,072 shares of common stock in exchange for the conversion of $446,109 of convertible debt and interest.  No gain or loss was recognized on the conversions as they occurred within the terms of the respective notes.

Business_Segments

Business Segments	12 Months Ended
	Mar. 31, 2014
Business Segments [Abstract]	'
Business Segments	'
	Note 11. Business Segments
	The Company has two reportable operating segments: (1) aquarium and aquarium supplies and (2) medical technology. These reportable segments are managed separately due to differences in their products.
	The only segment which generates revenue is aquarium and aquarium supplies. Management evaluates and monitors performance of this segment primarily through, among other measures, gross profit. The nanotechnology segment is in the development stage and has not begun to generate revenue.
	The results of operations and financial position of the two reportable operating segments and corporate were as follows:
	Results of Operations:
		Years ended
		March 31,
		2014			2013
	REVENUE
	Aquarium and aquarium supplies	$	113,009		$	100,186
	Medical technology		-			-
	Corporate		-			-
		$	113,009		$	100,186
	GROSS PROFIT (LOSS)
	Aquarium and aquarium supplies	$	(219	)	$	30,801
	Medical technology		-			-
	Corporate		-			-
		$	(219	)	$	30,801
	OPERATING EXPENSES
	Aquarium and aquarium supplies	$	144,788		$	88,550
	Medical technology		85,000			-
	Corporate		440,111			937,792
		$	669,899		$	1,026,342
	Corporate operating expense includes general and administrative costs not allocated to operating segments.
		March 31,
		2014			2013
	TOTAL ASSETS
	Aquarium and aquarium supplies	$	24,756		$	63,548
	Medical technology		-			-
	Corporate		52,989			83,710
		$	77,745		$	147,258

Subsequent_Events

Subsequent Events	12 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 12. Subsequent Events
	Convertible Notes
	In April and May, 2014, the holders of the Convertible Promissory Note signed September 30, 2013 elected to convert $160,000 in the aggregate of principal and accrued interest into five million shares of common stock at a rate of $0.04 per share. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement.  One million of the shares have not yet been issued.
	Subsequent to March 31, 2014, the Company has signed convertible promissory notes that refinance non-interest bearing advances into convertible notes payable. The convertible promissory notes bear interest at 10% per annum and are payable along with accrued interest. The convertible promissory notes and unpaid accrued interest are convertible into common stock at the option of the holder.
	Date Issued	Maturity Date	Interest Rate		Conversion Rate		Amount		Beneficial Conversion Feature
							of Note
	1-Apr-14	31-Mar-16	10	%	$	0.03	$	149,453		149,453
	30-Jun-14	30-Jun-16	10	%	$	0.02		62,980		62,980
	The Company evaluated the terms of the new notes in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity's Own Stock and determined that the underlying common stock is indexed to the Company's common stock. The Company determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion features and account for them as  separate derivative liabilities. The Company then evaluated the conversion features for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the notes and was deemed to be less than the market value of underlying common stock at the inception of the notes. Therefore, the Company recognized beneficial conversion discounts as shown in the table above. The beneficial conversion discounts were recorded as an increase in additional paid-in capital and a discount to the convertible notes payable. Discounts to the convertible notes payable are amortized to interest expense over the life of the notes.
	Nano3D Biosciences, Inc.
	On April 2, 2014, the Company entered into a common stock purchase agreement whereby the Company has agreed to acquire 132 shares of common stock of Nano3D Biosciences, Inc. for $64,938, at a purchase price of $413.62 per share.  This agreement may be cancelled by the Company with prior written notice to Nano3D Biosciences, Inc.  During April and May 2014, the Company paid Nano3D Biosciences, Inc. $20,000 for shares of its common stock pursuant to this agreement.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	12 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The Financial Statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles ("GAAP") of the United States.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the "Company"). All material intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	All cash is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Temporary cash investments with an original maturity of three months or less are considered cash equivalents. Cash and cash equivalents were $65,373 and $84,592 at March 31, 2014 and 2013, respectively.
Inventory	'
	Inventory
	The Company follows ASC 330, Inventory. Inventory represents aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence. During the year ended March 31, 2014, the Company recognized a loss for impairment of inventory in the amount of $14,500.
Fixed Assets	'
	Fixed Assets
	Fixed assets of the Company include vehicles and computer equipment and are stated at cost. In accordance with ASC Topic 360, Property, Plant and Equipment, expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred.
	Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value.
Goodwill	'
	Goodwill
	Goodwill represents the excess of purchase price and related costs over the value assigned to the net tangible and intangible assets of businesses acquired. We evaluate goodwill for impairment in accordance with ASC 350, Goodwill and Other. The Company recorded a goodwill impairment charge of $27,868 during the year ended March 31, 2014.
Revenue and Cost Recognition	'
	Revenue and cost recognition
	In accordance with ASC 605, Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances.
	Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products which have been sold.
Share-based Compensation Expense	'
	Share-based Compensation Expense
	The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity - Based Payments to Non-Employees.  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
	Share-based expense for the years ended March 31, 2014 and 2013 was $0 and $542,000, respectively.
Advertising Costs	'
	Advertising Costs
	The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $23,239 and $73,749 of advertising costs for the fiscal years ended March 31, 2014 and 2013, respectively.
Income Taxes	'
	Income Taxes
	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes resulting from temporary differences. Such temporary differences result from differences in the carrying value of assets and liabilities for tax and financial reporting purposes. The deferred tax assets and liabilities represent the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
	The Company adopted the provisions of FASB ASC 740-10 "Uncertainty in Income Taxes" (ASC 740-10). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.
Earnings (Loss) per Common Share	'
	Earnings (Loss) Per Common Share
	The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.  For the years ended March 31, 2014 and 2013, the effect of common stock equivalents has been excluded from the calculation of diluted earnings per share as their effect would be anti-dilutive.  At March 31, 2014 and 2013, respectively, the Company had 6,000,704 and 5,219,669 potentially issuable shares upon the conversion of convertible notes payable and interest.
Financial Instruments	'
	Financial Instruments
	The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.
	FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
		Level 1 -	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
		Level 2 -	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		Level 3 -	Inputs that are both significant to the fair value measurement and unobservable.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
Commitments and Contingencies	'
	Commitments and Contingencies
	The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no known commitments or contingencies as of March 31, 2014 and March 31, 2013.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	Recently issued or adopted accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Mar. 31, 2014
Convertible Notes Payable [Abstract]	'
Schedule of Convertible Notes Payable	'
	Convertible notes payable consist of the following as of March 31, 2014 and March 31, 2013:
		31-Mar-14			31-Mar-13
	Convertible note payable in the original principal amount of $192,600 due June 30, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.04 per share	$	4,742		$	-
	Convertible note payable in the original principal amount of $224,085 due Sepember 30, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.04 per share		224,085			-
	Convertible note payable in the original principal amount of $94,515, effective March 31, 2012 due March 31, 2014, bearing interest at 10% per year, convertible into common stock at a rate of $0.05 per share		-			4,515
	Convertible note payable in the original principal amount of $117,775, effective June 30, 2012 due June 30, 2014, bearing interest at 10% per year, convertible into common stock at a rate of $0.04 per share		-			73,275
	Convertible note payable in the original principal amount of $101,333, effective January 1, 2013 due January 1, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.05 per share		-			101,333
	Convertible note payable in the original principal amount of $43,575, effective March 31, 2013 due March 31, 2015, bearing interest at 10% per year, convertible into common stock at a rate of $0.05 per share		-			43,575
	Total convertible notes payable		228,827			222,698
	Less: current portion of convertible notes payable		-			(4,515	)
	Less: discount on noncurrent convertible notes payable		(215,716	)		(193,607	)
	Long-term convertible notes payable, net of discount	$	13,111		$	24,576
Schedule of Terms of Convertible Promissory Notes	'
	During the year ended March 31, 2014, the Company entered into convertible promissory notes with Vista View Ventures, Inc. which refinanced non-interest bearing advances. The convertible notes have the following terms:
	Note Date	Maturity Date		Interest Rate		Conversion Rate		Loan Amount
	30-Jun-13	30-Jun-15		10%		$0.04 per share		$192,600
	30-Sep-13	30-Sep-15		10%		$0.04 per share		$224,085

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Schedule of Income Tax Rate Reconciliation	'
	The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference at March 31, 2014 and 2013 are as follows.
		2014			2013
	Tax benefit at U.S. statutory rate	$	370,000		$	195,000
	Amortization of discount on convertible notes payable		(160,000	)		-
	Valuation allowance		(210,000	)		(195,000	)
		$	-		$	-

Business_Segments_Tables

Business Segments (Tables)	12 Months Ended
	Mar. 31, 2014
Business Segments [Abstract]	'
Schedule of Results of Operations by Reporting Segment	'
	The results of operations and financial position of the two reportable operating segments and corporate were as follows:
	Results of Operations:
		Years ended
		March 31,
		2014			2013
	REVENUE
	Aquarium and aquarium supplies	$	113,009		$	100,186
	Medical technology		-			-
	Corporate		-			-
		$	113,009		$	100,186
	GROSS PROFIT (LOSS)
	Aquarium and aquarium supplies	$	(219	)	$	30,801
	Medical technology		-			-
	Corporate		-			-
		$	(219	)	$	30,801
	OPERATING EXPENSES
	Aquarium and aquarium supplies	$	144,788		$	88,550
	Medical technology		85,000			-
	Corporate		440,111			937,792
		$	669,899		$	1,026,342
	Corporate operating expense includes general and administrative costs not allocated to operating segments.
		March 31,
		2014			2013
	TOTAL ASSETS
	Aquarium and aquarium supplies	$	24,756		$	63,548
	Medical technology		-			-
	Corporate		52,989			83,710
		$	77,745		$	147,258

Subsequent_Events_Tables

Subsequent Events (Tables)	12 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Schedule of Convertible Promissory Notes Used to Refinance Non-interest Bearing Deposits	'
	Subsequent to March 31, 2014, the Company has signed convertible promissory notes that refinance non-interest bearing advances into convertible notes payable. The convertible promissory notes bear interest at 10% per annum and are payable along with accrued interest. The convertible promissory notes and unpaid accrued interest are convertible into common stock at the option of the holder.
	Date Issued	Maturity Date	Interest Rate		Conversion Rate		Amount		Beneficial Conversion Feature
							of Note
	1-Apr-14	31-Mar-16	10	%	$	0.03	$	149,453		149,453
	30-Jun-14	30-Jun-16	10	%	$	0.02		62,980		62,980

Background_Information_Details

Background Information (Details) (USD $)	12 Months Ended		1 Months Ended	2 Months Ended	1 Months Ended		12 Months Ended			1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	31-May-14	Mar. 31, 2012	Apr. 30, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Feb. 28, 2013
			Nano3D Biosciences, Inc. ("N3D") [Member]	Nano3D Biosciences, Inc. ("N3D") [Member]	Nano3D Biosciences, Inc. ("N3D") [Member]	Nano3D Biosciences, Inc. ("N3D") [Member]	TheraKine Ltd. ("TheraKine") [Member]	TheraKine Ltd. ("TheraKine") [Member]	TheraKine Ltd. ("TheraKine") [Member]	TheraKine Ltd. ("TheraKine") [Member]
				Subsequent Event [Member]	Scenario, Plan [Member]	Scenario, Plan [Member]	First Phase [Member]	Second Phase [Member]	Second Phase [Member]	Scenario, Plan [Member]
						Subsequent Event [Member]			Subsequent Event [Member]	First Phase [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'
Shares acquired of joint venture's common stock	'	'	145	'	604	132	'	'	'	'
Percentage of outstanding stock acquired	'	'	'	'	5.00%	'	'	'	'	'
Common stock, price per share	'	'	'	'	$413.62	$413.62	'	'	'	'
Payments to joint venture	'	'	$60,000	$20,000	$249,826	$64,938	$55,000	$30,000	$20,000	$55,000
Weekly payments to joint venture	'	'	'	'	5,000	'	'	'	'	6,875
Expenses related to joint ventures and other business development agreements	$85,000	'	'	'	'	'	$55,000	$30,000	$20,000	'

Going_Concern_Details

Going Concern (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Going Concern [Abstract]	'	'
Net loss	$1,097,141	$1,263,190
Net cash used in operating activities	$531,818	$373,465

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Significant Accounting Policies [Abstract]	'	'	'
Cash and cash equivalents	$65,373	$84,592	$20,219
Impairment of inventory	14,500	'	'
Impairment of goodwill	27,868	'	'
Share-based expense	'	542,000	'
Advertising costs	23,239	73,749	'
Potentially issuable shares upon the conversion of convertible notes payable and interest	6,000,704	5,219,669	'
Commitments and contingencies	'	'	'
Minimum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated Useful Lives	'3 years	'	'
Maximum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated Useful Lives	'5 years	'	'

Inventory_Details

Inventory (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Inventory [Abstract]	'	'
Impairment of inventory	$14,500	'

Advances_Details

Advances (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Advances [Abstract]	'	'
Proceeds from advances	$432,683	$396,138
Refinancing of advances into convertible notes payable	416,685	445,434
Advances payable	$149,453	$133,455

Convertible_Notes_Payable_Narr

Convertible Notes Payable (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Debt Conversion [Line Items]	'	'
Beneficial conversion on convertible note payable	$416,685	$445,434
Proceeds from advances	432,683	396,138
Convertible note payable effective March 31, 2012 [Member]	'	'
Debt Conversion [Line Items]	'	'
Amount of note principal converted	4,515	'
Amount of note interest converted	6,934	'
Debt conversion, shares issued	228,983	'
Debt instrument, conversion price per share	$0.05	'
Convertible note payable effective June 30, 2012 [Member]	'	'
Debt Conversion [Line Items]	'	'
Amount of note principal converted	73,275	'
Amount of note interest converted	8,702	'
Debt instrument, conversion price per share	$0.04	'
Convertible note payable effective January 1, 2013 [Member]	'	'
Debt Conversion [Line Items]	'	'
Amount of note principal converted	101,333	'
Amount of note interest converted	5,354	'
Debt instrument, conversion price per share	$0.05	'
Convertible note payable effective March 31, 2013 [Member]	'	'
Debt Conversion [Line Items]	'	'
Amount of note principal converted	43,575	'
Amount of note interest converted	2,421	'
Debt instrument, conversion price per share	$0.05	'
Convertible note payable effective June 30, 2013 [Member]	'	'
Debt Conversion [Line Items]	'	'
Amount of note principal converted	187,858	'
Amount of note interest converted	$12,142	'
Debt instrument, conversion price per share	$0.04	'

Convertible_Notes_Payable_Sche

Convertible Notes Payable (Schedule of Convertible Notes Payable) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Debt Instrument [Line Items]	'	'
Total convertible notes payable	$228,827	$222,698
Less: current portion of convertible notes payable	'	-4,515
Less: discount on noncurrent convertible notes payable	-215,716	-193,607
Long-term convertible notes payable, net of discount	13,111	24,576
Convertible note payable effective June 30, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	4,742	'
Debt instrument, face amount	192,600	'
Debt instrument, effective date	30-Jun-13	'
Debt instrument, maturity date	30-Jun-15	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.04	'
Convertible note payable effective September 30, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	224,085	'
Debt instrument, face amount	224,085	'
Debt instrument, effective date	30-Sep-13	'
Debt instrument, maturity date	30-Sep-15	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.04	'
Convertible note payable effective March 31, 2012 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	'	4,515
Debt instrument, face amount	94,515	'
Debt instrument, effective date	31-Mar-12	'
Debt instrument, maturity date	31-Mar-14	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.05	'
Convertible note payable effective June 30, 2012 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	'	73,275
Debt instrument, face amount	117,775	'
Debt instrument, effective date	30-Jun-12	'
Debt instrument, maturity date	30-Jun-14	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.04	'
Convertible note payable effective January 1, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	'	101,333
Debt instrument, face amount	101,333	'
Debt instrument, effective date	1-Jan-13	'
Debt instrument, maturity date	1-Jan-15	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.05	'
Convertible note payable effective March 31, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	'	43,575
Debt instrument, face amount	$43,575	'
Debt instrument, effective date	31-Mar-13	'
Debt instrument, maturity date	31-Mar-15	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.05	'

Longterm_note_payable_Details

Long-term note payable (Details) (USD $)	1 Months Ended
	Dec. 31, 2013
Long-term note payable [Abstract]	'
Long-term promissory note	$50,000
Interest on long-term promissory note	5.00%
Installment payments start date	1-Jan-15
Initial term of loan	'4 years

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Related Party Transactions [Abstract]	'	'
Related party advances payable	$131,505	$94,881

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Taxes [Abstract]	'	'
Current income tax expense	'	'
Deferred income tax expense	'	'
Income tax rate reconciliation:	'	'
Tax benefit at U.S. statutory rate	370,000	195,000
Amortization of discount on convertible notes payable	-160,000	'
Valuation allowance	-210,000	-195,000
Income tax expense	'	'
IRS [Member] | Minimum [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Open tax years	'2011	'
IRS [Member] | Maximum [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Open tax years	'2014	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 05, 2012
Stockholders' Equity [Abstract]	'	'	'
2012 Stock plan, shares authorized	'	'	6,000,000
Stock-based compensation	'	$542,000	'
Common stock issued for services, shares	80,000	'	'
Conversion of notes payable, shares	10,332,072	'	'
Conversion of notes payable	$446,109	$224,022	'

Business_Segments_Details

Business Segments (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenue	$113,009	$100,186
Gross profit (loss)	-219	30,801
Operating expenses	669,899	1,026,342
Total assets	77,745	147,258
Aquarium And Aquarium Supplies [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	113,009	100,186
Gross profit (loss)	-219	30,801
Operating expenses	144,788	88,550
Total assets	24,756	63,548
Medical Technology [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	'	'
Gross profit (loss)	'	'
Operating expenses	85,000	'
Total assets	'	'
Corporate [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	'	'
Gross profit (loss)	'	'
Operating expenses	440,111	937,792
Total assets	$52,989	$83,710

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	12 Months Ended		1 Months Ended		12 Months Ended	2 Months Ended	1 Months Ended	2 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2012	Mar. 31, 2014	31-May-14	Apr. 30, 2014	31-May-14	31-May-14	Mar. 31, 2014	Mar. 31, 2014
			Nano Three Dimensional Biosciences Inc Joint Venture [Member]	Nano Three Dimensional Biosciences Inc Joint Venture [Member]	Convertible note payable effective September 30, 2013 [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Scenario, Plan [Member]		Nano Three Dimensional Biosciences Inc Joint Venture [Member]	Nano Three Dimensional Biosciences Inc Joint Venture [Member]	Convertible note payable effective September 30, 2013 [Member]	Convertible note payable effective September 30, 2013 [Member]	Convertible note payable effective April 1, 2014 [Member]	Convertible note payable effective June 30, 2014 [Member]
							Scenario, Plan [Member]		Scenario, Plan [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Amount of debt converted	'	'	'	'	'	'	'	$160,000	'	'	'
Debt conversion, shares issued	'	'	'	'	'	'	'	'	5,000,000	'	'
Debt instrument, conversion price per share	'	'	'	'	$0.04	'	'	$0.04	'	$0.03	$0.02
Debt conversion, shares to be issued	'	'	'	'	'	'	'	1,000,000	'	'	'
Debt instrument, effective date	'	'	'	'	30-Sep-13	'	'	'	'	1-Apr-14	30-Jun-14
Debt instrument, maturity date	'	'	'	'	30-Sep-15	'	'	'	'	31-Mar-16	30-Mar-16
Debt instrument, interest rate	'	'	'	'	10.00%	'	'	'	'	10.00%	10.00%
Debt instrument, face amount	'	'	'	'	224,085	'	'	'	'	149,453	62,980
Beneficial conversion on convertible note payable	416,685	445,434	'	'	'	'	'	'	'	149,453	62,980
Shares acquired of joint venture's common stock	'	'	145	604	'	'	132	'	'	'	'
Payments to joint venture	'	'	$60,000	$249,826	'	$20,000	$64,938	'	'	'	'
Common stock, price per share	'	'	'	$413.62	'	'	$413.62	'	'	'	'